Research Analysts’ Recent Ratings Changes for Apellis Pharmaceuticals (APLS)

Posted by James Quigley on May 27th, 2025

Several brokerages have updated their recommendations and price targets on shares of Apellis Pharmaceuticals (NASDAQ: APLS) in the last few weeks:

5/22/2025 – Apellis Pharmaceuticals had its price target lowered by analysts at Citigroup Inc. from $49.00 to $41.00. They now have a “buy” rating on the stock.
5/14/2025 – Apellis Pharmaceuticals had its price target lowered by analysts at Mizuho from $30.00 to $20.00. They now have a “neutral” rating on the stock.
5/9/2025 – Apellis Pharmaceuticals was downgraded by analysts at Raymond James from a “strong-buy” rating to an “outperform” rating. They now have a $52.00 price target on the stock, down previously from $75.00.
5/9/2025 – Apellis Pharmaceuticals was downgraded by analysts at Bank of America Co. from a “buy” rating to a “neutral” rating. They now have a $23.00 price target on the stock, down previously from $41.00.
5/8/2025 – Apellis Pharmaceuticals had its price target lowered by analysts at Royal Bank of Canada from $21.00 to $18.00. They now have a “sector perform” rating on the stock.
5/8/2025 – Apellis Pharmaceuticals had its price target lowered by analysts at Scotiabank from $28.00 to $20.00. They now have a “sector perform” rating on the stock.
5/8/2025 – Apellis Pharmaceuticals had its price target lowered by analysts at Robert W. Baird from $55.00 to $47.00. They now have an “outperform” rating on the stock.
5/8/2025 – Apellis Pharmaceuticals had its price target lowered by analysts at Wells Fargo & Company from $30.00 to $26.00. They now have an “equal weight” rating on the stock.
5/7/2025 – Apellis Pharmaceuticals had its price target lowered by analysts at Needham & Company LLC from $40.00 to $29.00. They now have a “buy” rating on the stock.
4/29/2025 – Apellis Pharmaceuticals is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $44.00 price target on the stock.
4/21/2025 – Apellis Pharmaceuticals had its price target lowered by analysts at Royal Bank of Canada from $24.00 to $21.00. They now have a “sector perform” rating on the stock.
4/2/2025 – Apellis Pharmaceuticals had its price target raised by analysts at Scotiabank from $30.00 to $31.00. They now have a “sector perform” rating on the stock.

Apellis Pharmaceuticals Trading Down 3.2%

Shares of Apellis Pharmaceuticals stock traded down $0.55 during mid-day trading on Tuesday, hitting $16.89. The stock had a trading volume of 1,952,718 shares, compared to its average volume of 2,265,735. The firm has a market cap of $2.12 billion, a P/E ratio of -8.32 and a beta of 0.73. Apellis Pharmaceuticals, Inc. has a 12-month low of $16.10 and a 12-month high of $43.76. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. The firm has a 50-day moving average of $19.47 and a two-hundred day moving average of $26.23.

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The firm had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business’s revenue was down 3.2% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.54) earnings per share. Sell-side analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Activity

In related news, General Counsel David O. Watson sold 5,569 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $25.10, for a total value of $139,781.90. Following the completion of the sale, the general counsel now owns 138,730 shares in the company, valued at $3,482,123. This trade represents a 3.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 6.50% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Teacher Retirement System of Texas increased its stake in shares of Apellis Pharmaceuticals by 9.4% during the 4th quarter. Teacher Retirement System of Texas now owns 21,649 shares of the company’s stock valued at $691,000 after acquiring an additional 1,864 shares during the last quarter. KBC Group NV increased its position in Apellis Pharmaceuticals by 3,862.3% during the fourth quarter. KBC Group NV now owns 104,287 shares of the company’s stock worth $3,328,000 after purchasing an additional 101,655 shares during the last quarter. Entropy Technologies LP acquired a new position in Apellis Pharmaceuticals during the fourth quarter worth approximately $445,000. Barclays PLC increased its holdings in shares of Apellis Pharmaceuticals by 18.0% during the 3rd quarter. Barclays PLC now owns 255,897 shares of the company’s stock worth $7,381,000 after buying an additional 39,019 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of Apellis Pharmaceuticals by 2.6% during the 4th quarter. Ameriprise Financial Inc. now owns 882,801 shares of the company’s stock worth $28,170,000 after buying an additional 22,507 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).